4XDK

Crystal structure of human two pore domain potassium ion channel TREK2 (K2P10.1) in complex with norfluoxetine


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.60 Å
  • R-Value Free: 0.254 
  • R-Value Work: 0.248 
  • R-Value Observed: 0.248 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac.

Dong, Y.Y.Pike, A.C.Mackenzie, A.McClenaghan, C.Aryal, P.Dong, L.Quigley, A.Grieben, M.Goubin, S.Mukhopadhyay, S.Ruda, G.F.Clausen, M.V.Cao, L.Brennan, P.E.Burgess-Brown, N.A.Sansom, M.S.Tucker, S.J.Carpenter, E.P.

(2015) Science 347: 1256-1259

  • DOI: 10.1126/science.1261512
  • Primary Citation of Related Structures:  
    4BW5, 4XDJ, 4XDK, 4XDL

  • PubMed Abstract: 
  • TREK-2 (KCNK10/K2P10), a two-pore domain potassium (K2P) channel, is gated by multiple stimuli such as stretch, fatty acids, and pH and by several drugs. However, the mechanisms that control channel gating are unclear. Here we present crystal structures of the human TREK-2 channel (up to 3 ...

    TREK-2 (KCNK10/K2P10), a two-pore domain potassium (K2P) channel, is gated by multiple stimuli such as stretch, fatty acids, and pH and by several drugs. However, the mechanisms that control channel gating are unclear. Here we present crystal structures of the human TREK-2 channel (up to 3.4 angstrom resolution) in two conformations and in complex with norfluoxetine, the active metabolite of fluoxetine (Prozac) and a state-dependent blocker of TREK channels. Norfluoxetine binds within intramembrane fenestrations found in only one of these two conformations. Channel activation by arachidonic acid and mechanical stretch involves conversion between these states through movement of the pore-lining helices. These results provide an explanation for TREK channel mechanosensitivity, regulation by diverse stimuli, and possible off-target effects of the serotonin reuptake inhibitor Prozac.


    Organizational Affiliation

    Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, UK. OXION Initiative in Ion Channels and Disease, University of Oxford, Oxford OX1 3PN, UK. liz.carpenter@sgc.ox.ac.uk stephen.tucker@physics.ox.ac.uk.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Potassium channel subfamily K member 10A, B, C, D282Homo sapiensMutation(s): 0 
Gene Names: KCNK10TREK2
Membrane Entity: Yes 
UniProt & NIH Common Fund Data Resources
Find proteins for P57789 (Homo sapiens)
Explore P57789 
Go to UniProtKB:  P57789
PHAROS:  P57789
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 4 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
PC1 (Subject of Investigation/LOI)
Query on PC1

Download Ideal Coordinates CCD File 
H [auth A], I [auth A], M [auth B], N [auth B]1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE
C44 H88 N O8 P
NRJAVPSFFCBXDT-HUESYALOSA-N
 Ligand Interaction
405 (Subject of Investigation/LOI)
Query on 405

Download Ideal Coordinates CCD File 
K [auth A], L [auth A], T [auth C], V [auth C](3S)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
C16 H16 F3 N O
WIQRCHMSJFFONW-HNNXBMFYSA-N
 Ligand Interaction
408 (Subject of Investigation/LOI)
Query on 408

Download Ideal Coordinates CCD File 
J [auth A], O [auth B], S [auth C], U [auth C](3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
C16 H16 F3 N O
WIQRCHMSJFFONW-OAHLLOKOSA-N
 Ligand Interaction
K
Query on K

Download Ideal Coordinates CCD File 
E [auth A], F [auth A], G [auth A], P [auth C], Q [auth C], R [auth C]POTASSIUM ION
K
NPYPAHLBTDXSSS-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.60 Å
  • R-Value Free: 0.254 
  • R-Value Work: 0.248 
  • R-Value Observed: 0.248 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 75.19α = 90
b = 113.03β = 90.41
c = 112.5γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
xia2data reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment  



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Wellcome TrustUnited Kingdom092809/Z/10/Z

Revision History  (Full details and data files)

  • Version 1.0: 2015-03-18
    Type: Initial release
  • Version 1.1: 2015-04-01
    Changes: Database references
  • Version 1.2: 2018-01-10
    Changes: Structure summary